What does Enasidenib Mesylate (Idhifa) do in plain English—and how does it work inside your body?
Enasidenib Mesylate is an FDA-regulated Isocitrate Dehydrogenase 2 Inhibitor (RxNorm RxCUI RXN-59572710-2669). Mechanistically, Enasidenib Mesylate exerts selective isocitrate dehydrogenase 2 inhibitor pharmacodynamic activity across 100 mg/1 Tablet, Film Coated and 50 mg/1 Tablet, Film Coated (oral-route route, manufactured/labeled by Celgene Corporation), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 59572-710, 59572-705). [1][2].
When your doctor writes a prescription for Enasidenib Mesylate (RxNorm RxCUI RXN-59572710-2669, also dispensed under brand names including Idhifa), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, Enasidenib Mesylate exerts selective isocitrate dehydrogenase 2 inhibitor pharmacodynamic activity across 100 mg/1 Tablet, Film Coated and 50 mg/1 Tablet, Film Coated (oral-route route, manufactured/labeled by Celgene Corporation), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 59572-710, 59572-705). [2].
Across real-world patient logs on dotMD (84% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Enasidenib Mesylate tablet bottle and confirm with your pharmacist that it matches your prescribed strength (100 mg/1 Tablet, Film Coated, 50 mg/1 Tablet, Film Coated).